Cipla Q3 show pulls up Nifty Pharma 2%, Sun Pharma among top gainers

Other major pharma names like Sun Pharma, Lupin, Dr Reddy's and Zydus Life were up 2-4 percent.

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Shares of pharma companies surged in trade on January 23 after industry major Cipla's strong Q3 earnings sparked hopes of a similar show from other drugmakers. The gains across major pharma stocks also lifted the Nifty Pharma index nearly 2 percent higher despite weak market conditions.

At close of the day, the Nifty Pharma index was up 1.66 percent at 17,520.30 driven by shares of Cipla, which were the top Nifty 50 gainers with uptick of over 6 percent. Other major pharma names such as Sun Pharma, Lupin, Dr Reddy's, and Zydus Life were up 2-4 percent.

Drugmaker Cipla posted a strong performance in Q3 on all key parameters of profit, revenue, and profitability.

The company's net profit for the quarter grew 32.7 percent on year to Rs 1,049 crore despite an exceptional loss of Rs 194.8 crore. The topline rose 14.2 percent on year with revenue coming in at Rs 6,544 crore in the October-December period.

What's more encouraging is that Q3 also marked well rounded growth for the company in all its key markets. Its highest ever North American sales at $230 million, up 18 percent on year benefitting from continued momentum in key assets and robust demand in base business along with some year-end buying.

The India business also grew nearly 12 percent on year driven by a strong performance across branded prescription, trade generics, and consumer health. South Africa too recorded a near 10 percent rise, enjoying the  increase in revenue in local currency terms.

The strong growth in the India business also sparked hopes of a recovery in domestic sales for other pharma players as well. Its worth noting that domestic pharma sales remained sluggish in the previous quarter, thereby moderating the revenue and profit growth reported by most drugmakers.